ASH 2023 | Secondary cytogenetic abnormalities in MM: prognostic value of chromosome 1q gain vs amplification
Rafael Fonseca, MD, Mayo Clinic, Phoenix, AZ, discusses the findings of an investigation into secondary cytogenetic abnormalities in multiple myeloma (MM) and comments on their prognostic value. Fluorescent In-Situ Hybridization (FISH)-based cytogenetic profiling was performed in samples from over 2000 patients, and an association was found between an increasing number of chromosome 1q copies and reduced overall survival (OS). Dr Fonseca emphasizes the need to differentiate between 1q ‘gain’ (3 copies) and ‘amplification’ (≥ 4 copies) when defining high-risk patients, as amplification led to a significantly poorer prognosis and decreased OS. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Takeda, Janssen, Binding Site, Millenium, BMS (Celgene), Sanofi, Regeneron, Pharmacyclics, Pfizer, Merck, Kite, Juno, Bayer, Aztrazeneca, AMGEN, Adaptive Biotechnologies, AbbVie
Membership on Board of Directors/Advisory Committee: AZBio, Antegene, Oncotracker, Caris Life Sciences, Adaptive Biotechnologies
Patents & Royalties: FISH
